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The art and science of drug titration
Aisling R. Caffrey

and Eric P. Borrelli

Abstract
A “one-size-fits-all” approach has been the standard for drug dosing, in particular for agents
with a wide therapeutic index. The scientific principles of drug titration, most commonly
used for medications with a narrow therapeutic index, are to give the patient adequate and
effective treatment, at the lowest dose possible, with the aim of minimizing unnecessary
medication use and side effects. The art of drug titration involves the interplay of scientific
drug titration principles with the clinical expertise of the healthcare provider, and an
individualized, patient-centered partnership between the provider and the patient to review
the delicate balance of perceived benefits and risks from both perspectives. Drug titration
may occur as up-, down-, or cross-titration depending on whether the goal is to reach or
maintain a therapeutic outcome, decrease the risk of adverse effects, or prevent withdrawal/
discontinuation syndromes or recurrence of disease. Drug titration introduces additional
complexities surrounding the conduct of clinical trials and real-world studies, confounding
our understanding of the true effect of medications. In clinical practice, wide variations in
titration schedules may exist due to a lack of evidence and consensus on titration approaches
that achieve an optimal benefit-harm profile. Further, drug titration may be challenging for
patients to follow, resulting in suboptimal adherence and may require increased healthcarerelated visits and coordination of care amongst providers. Despite the challenges associated
with drug titration, it is a personalized approach to drug dosing that blends science with art,
and with supportive real-world outcomes-based evidence, can be effective for optimizing
pharmacotherapeutic outcomes and improving drug safety.
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Plain language summary
The art and science of finding the right dose
Summary: Changes to medication doses to achieve the best clinical response is known
as drug titration. Drug titration is a way for clinicians to personalize medication doses
so that patients can obtain the intended benefits of the treatment of their disease while
minimizing side effects. This can occur by increasing the dose of a medication over time
(up-titrating) until symptom relief occurs or a certain laboratory value is met, indicating
that the most appropriate dose for that patient has been found. On the other hand, it
can mean decreasing the dose of a medication over time (down-titrating) to lessen side
effects or to find the lowest possible dose that keeps a patient’s symptoms or laboratory
values under control. At times, up- and down-titrating may occur at the same time
when one medication is being stopped and another is being started (cross-titration). For
many medications, there may be limited scientific evidence to guide clinicians on the
best schedule for changing medication doses. Further, dose changes can be difficult for
clinicians to explain and for patients to follow. In addition, without proper coordination of
care between providers, it may be difficult to properly manage adverse effects. Electronic
health record systems need to implement new structures that capture medication dose
changes, allowing better coordination of care and titration studies to identify schedules
that achieve better patient outcomes and improve medication safety.
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Introduction
Establishing the precise dose for a drug is a complex process. Historically, a single-dose regimen
has been selected for agents with a wide therapeutic
window, as minor changes in drug concentrations
would have a limited impact on the efficacy and
safety of the medication.1–3 However, a single-dose
“one-size-fits-all” approach may not be equally
effective and safe in all patients, and, therefore,
multiple patient-level factors likely influence the
optimal dose for an individual patient. Individual
patient characteristics, including genetics, age,
weight, renal and hepatic function, co-morbidities,
and co-administration of other drugs, affect the
dose a particular patient may require for a favorable
risk–benefit ratio.4,5 In addition, pharmacokinetic
(PK) (dose-concentration relationship) and pharmacodynamic (PD) (concentration-effect relationship) factors affect the amount of drug required,2,4,6
including absorption, bioavailability, distribution,
metabolism, and excretion, along with the mechanism of action and the magnitude and duration of
the clinical effect of the drug.5,7
Drug titration is a more individualized, patientcentered approach to dosing, and is used in multiple therapeutic areas. Drug titration is common
for agents with a narrow therapeutic index in
order to optimize the therapeutic benefit while
minimizing the risk of adverse effects, including
drug–drug interactions.3,5 Some classic examples
of drugs that require titration include antibiotics
(e.g., aminoglycosides, vancomycin),8,9 anticoagulants (e.g., warfarin),10 anticonvulsants (e.g.,
phenytoin),11 antidepressants (e.g., paroxetine),12
antidiabetics (e.g., insulin, metformin),13 antipsychotics (e.g., quetiapine),14 opioids (e.g,. morphine),15 and stimulants (e.g., amphetamines).16
In this narrative review, we discuss types of drug
titration, titration schedules, challenges in drug
titration, and opportunities to improve the art
and science of drug titration.
Drug titration
Drug titration versus dose adjustment
Drug titration may be based on PK/PD parameters, achievement of therapeutic outcomes, results
2

of pharmacogenetic testing (PGT), and/or maintenance of drug safety.2,3,17 It is important to keep
in mind the distinction between drug titration
and dose adjustment. A dose adjustment is necessary to maintain appropriate drug concentrations
despite alterations in PK/PD parameters due to
innate or external factors such as age, body weight
(actual, ideal, or adjusted), drug interactions,
metabolism, plasma protein binding, or renal/
hepatic impairment.2,3 Dose adjustment recommendations can be found in prescribing information and usually occur without a titration. For
example, the dose of intravenous ciprofloxacin for
an adult patient with chronic renal failure on
hemodialysis is 400 mg every 24 h as compared
with a dose of 400 mg every 12 h when a patient’s
creatinine clearance (Clcr) is >30 ml/min for most
infections.18,19 The recommended dose of rimantadine for influenza A prophylaxis in the elderly is
100 mg orally daily (as opposed to twice daily),
and the high-dose influenza vaccine is specifically
approved for patients 65 years and older.20,21 The
administration of efavirenz and voriconazole concurrently is an example of a dose adjustment
based on a drug–drug interaction. Efavirenz
[always administered in combination with other
antiretrovirals to provide a complete human
immunodeficiency virus (HIV) regimen] is
adjusted down to 300 mg/day orally when it is
administered simultaneously with voriconazole,
and the voriconazole dose is increased to 400 mg
orally every 12 h.22 Lastly, ethambutol illustrates
a dose adjustment based on weight: for patients
weighing 40–55 kg, the recommended daily oral
dose is 800 mg, for patients weighing 56–75 kg,
the dose is 1200 mg, and for patients weighing
76–90 kg, the dose is 1600 mg.23
Drug titration, in the traditional, scientific sense,
is a change in dosing based on a specific PK/PD,
clinical, pharmacogenetic, or laboratory parameter, or is based on a set titration schedule as per
the prescribing information. It is dosing that is
individualized to the specific patient, with the goal
of reaching a specific laboratory or clinical target
with the lowest dose possible, while mitigating
adverse effects, and/or preventing withdrawal/discontinuation symptoms or disease recurrence. It
may be accomplished via up-titration (increasing
journals.sagepub.com/home/taw
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the dose over time), down-titration (decreasing
the dose over time), or cross-titration (decreasing
the dose of one drug while at the same time
increasing the dose of another drug).3 A classic
example of titration is the dosing of aminoglycosides and vancomycin based on therapeutic drug
concentrations. In general, gentamicin is dosed
based on ideal body weight, starting with a loading
dose of 1.5–2 mg/kg intravenously, followed by
1–1.7 mg/kg (3–5 mg/kg/day) every 8 h with subsequent dose adjustments based on peak and trough
concentrations and the minimum inhibitory concentration (MIC) of the bacterial pathogen.8 The
goal is to maximize the peak concentration to
MIC ratio (⩾8:1–10:1) to optimize bacterial killing.24 Vancomycin is dosed based on actual body
weight, starting with a loading dose of 20–35 mg/
kg in critically ill patients, followed by 15–20 mg/
kg/dose every 8–12 h with subsequent dose adjustments based on the ratio of the area under the
curve (AUC) to the MIC of the bacterial pathogen.9 The aim of this dosing strategy is to sustain
an AUC/MIC ratio of 400–600 for methicillinresistant Staphylococcus aureus infections to have
the best chance of clinical treatment success with
decreased potential for nephrotoxicity.9 Further,
PGT plays a role in tailoring both drug selection
and dosing with the intent of optimizing effectiveness and minimizing adverse effects.17 PGT
has been shown to be potentially helpful in
these respects with anesthestics, anticonvulsants,
antidepressants, antineoplastics, antiretrovirals,
attention deficit hyperactivity disorder (ADHD)
medications, mood stabilizers, and warfarin.17,25–31
The art versus science of drug titration
The scientific principles of drug titration are to
give the patient adequate and effective treatment,
at the lowest dose possible, with the aim of minimizing unnecessary medication use and side
effects.2,3 The art of drug titration involves the
interplay of scientific drug titration principles
with the clinical expertise of the healthcare provider, and an individualized, patient-centered
partnership between the provider and the patient
to review the delicate balance of perceived benefits and risks from both perspectives. The art
therefore takes into consideration what is realistic
for a particular patient, including the intended
therapeutic outcomes and management of drug
titration based on each patient’s unique circumstances. This is an individualized approach that
includes compromise and recognizes the patient’s
journals.sagepub.com/home/taw

autonomy, and evaluates the impact of positive
and negative clinical outcomes, not just PK/PD
and laboratory measurements. The patient factors that should be taken into account during the
decision-making process may include, but are not
limited to, the titration complexity, the patient’s
expectations related to drug effectiveness and
when therapeutic outcomes should occur, the
severity of the disease, co-morbidities, concurrent
medications, consequences of non-adherence,
potential for and seriousness of adverse effects,
personal priorities, health literacy, and socioeconomic status. These factors inherently influence a
patient’s willingness to adhere to a drug titration
schedule, without which the benefits of the medication will not come to fruition.3,32–35 Artistry,
rooted in scientific evidence, is used to select the
most appropriate titration schedule for an individual patient, in particular when multiple strategies exist or strategies are less well-defined.
Titration schedule
The information regarding how to manage drug
titration is usually provided in the prescribing
information for the drug, evidence-based clinical
practice guidelines, or various drug information
resources. For some medications, set titration
schedules may be recommended by the manufacturer, as found in the product label. Dose packs
facilitate adherence by providers and patients to
these recommended titration schedules, as seen
with methylprednisolone and azithromycin.3,35–37
Alternatively, response-guided titration may be
used alone or in combination with target titration
schedules per the package insert, as with antiepileptic drugs.38 Ideally, for a response-guided
approach to titrated drug dosing, there is an
objective marker to measure the laboratory or
clinical parameter of interest that guides the titration schedule.2 Example laboratory markers that
guide titration include target international normalized ratio (INR) with warfarin,39 target phenytoin concentration with phenytoin,11 and target
blood glucose concentrations during daily testing
and hemoglobin A1c for long-term monitoring
with insulin and oral diabetes medications.40
When available, dosing algorithms based on PGT
can be used to optimize the dose for individual
patients, as has been demonstrated with warfarin
and phenytoin.10,41,42 Clinical parameters may
also be used to facilitate drug titration. Examples
include antiepileptic drug doses titrated based on
the reduction in seizure frequency or seizure
3
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freedom,43 and antidepressants or opioids titrated
based on scales that assess clinical response, such
as the Hamilton Depression Rating Scale or the
Visual Analog Scale, respectively.12,15
Providers may need to make exceptions to recommended titration schedules and treatment goals
as they may not meet the needs of all patients.
The recommendations may be used as a starting
point, with modifications made based on a
patient’s specific needs. For example, when treating diabetes, hypertension, and hypercholesterolemia, the adverse effect profiles of the drugs
used to treat these diseases influence how aggressive or cautious providers and patients may want
to be with drug doses and titration schedules.
There may be compromises to allow some degree
of hyperglycemia to decrease the risk of hypoglycemia, some degree of hypertension to minimize
the risk of hypotension, and some degree of
hypercholesterolemia to prevent liver enzyme elevations or myopathy.1 This type of customization,
which showcases drug titration as a fusion of science and art, is necessary to achieve effectiveness
and maintain patient safety.
Up-titration
Up-titration is characterized by initiating therapy
at a lower dose and increasing the dose over time
to maintain or attain a specific response, or to
decrease the risk of adverse effects. An example of
up-titration to a specific therapeutic goal is the
use of norepinephrine in the setting of sepsis and
septic shock. The dose of norepinephrine is
titrated up to achieve a mean arterial pressure of
65 mmHg.44 Another example is semaglutide for
the treatment of type 2 diabetes. The dose of
semaglutide is titrated up to achieve glycemic
control. Starting with an initial dose of 0.25 mg
subcutaneously once weekly for 4 weeks, the dose
is then increased to 0.5 mg once weekly for at
least 4 weeks, and further increased to 1 mg once
weekly if needed.45 Likewise, the oral semaglutide
formulation also requires up-titration, beginning
with a dose of 3 mg orally once daily for 30 days,
followed by 7 mg orally once daily for 30 days. If
additional glycemic control is needed, the dose
may be increased to 14 mg orally once daily thereafter.46 With up-titration towards a specific therapeutic goal, it is important to keep in mind that
there may be a point at which there is a ceiling
effect in the response and continuing to increase
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the dose will not increase the effect, and may, in
turn, put a patient at higher risk of adverse
effects.3
Up-titration may be used to mitigate adverse
effects. An example in oncology is the recommended titration schedule for venetoclax, an
agent used for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma.
In order to prevent tumor lysis syndrome from
occurring, dosing with venetoclax is initiated at
20 mg/day orally in week 1, then increased to
50 mg/day in week 2, 100 mg/day in week 3,
200 mg/day in week 4, and then 400 mg/day in
week 5.47 Antiepileptic drugs are also up-titrated
to minimize adverse effects. Perampanel dosing is
started at 2 mg/day orally at bedtime with an uptitration of 2 mg per week to achieve a target of
4–12 mg/day to minimize dizziness.43 Lamotrigine
is gradually up-titrated to reduce the risk of rash,
in particular Stevens-Johnson syndrome or toxic
epidermal necrolysis. There are 5-week starter kits
available to assist patients with adherence to the
titration schedule and specific dose titrations are
recommended based on the patient’s age, weight,
and concurrent medications.48 Antidepressants
are another class of drugs that require up-titration
to reduce adverse effects. Selective serotonin
reuptake inhibitors are started at a lower dose and
up-titrated over time to reduce the development
of anxiety.49
Up-titration may also be necessary based on a
specific PK/PD parameter. Carbamazepine
undergoes self-induction of hepatic enzymes,
which leads to an increase in its metabolism over
time, thereby requiring an increase in dose over
time in order to maintain appropriate concentrations and a therapeutic effect.50 In contrast,
patients with genetic variants of the cytochrome
P450 enzymes CYP2C9*2 and CYP2C9*3 have a
reduced ability to metabolize warfarin. Patients
with these variants should be initially treated with
a lower dose of warfarin and up-titrated more
cautiously as they are at higher risk of developing
supra-therapeutic international normalized ratios
(INRs) and adverse effects.10
Up-titration may also be used for gradual
improvement of symptoms or clinical outcomes
while monitoring for adverse effects, particularly
when optimal clinical effectiveness comes at the
cost of dose-related side effects for drugs with

journals.sagepub.com/home/taw

AR Caffrey and EP Borrelli et al.
relatively narrow and specific therapeutic windows.3 The art is in the partnership between the
provider and patient for the management of side
effects and occurs through the assessment of
patient expectations and tolerance, as related to
both presence and severity of negative effects.
Therefore, the art includes the evaluation of any
problems that the patient is experiencing to determine whether the dose is too high, too low, of
insufficient duration to experience positive effects
and/or for side effects to subside, and/or ineffective for that particular patient. This is demonstrated in the treatment of ADHD, whereby
treatment guidelines recommend four different
approaches to up-titration: increasing the dose up
to a dose beyond which there is no further
improvement in symptoms, increasing the dose
until the lowest dose that provides a response is
achieved, increasing the dose until the maximum
dose is reached, or increasing the dose until adverse
effects occur.51 The success of the approach chosen relies on communication between the provider and the patient at the onset of titration,
continual input from the patient over the course
of the titration, and a mutual understanding of
the need for flexibility in the up-titration schedule to maintain patient adherence.3 Based on
the information the patient provides regarding
symptom control and tolerability, the provider
can alter the titration if doses are sub- or supratherapeutic. For this to occur, it is critical to
have the patient’s (or patient proxy, e.g., parent) assessment of the level of effectiveness of
their functioning on different doses so subsequent titration is guided by input from the
patient.
Down-titration
Down-titration is characterized by decreasing the
dose over time once a specific response has been
achieved, to either maintain a specific response
while decreasing the risk of adverse effects or to
prevent withdrawal or discontinuation syndromes. There are many examples of medications
for immunologic and inflammatory diseases that
may require a dose decrease once their specific
therapeutic goal has been achieved. Infliximab is
a tumor necrosis factor inhibitor used to treat
rheumatoid arthritis.52 In patients with stable low
disease activity or disease remission, infliximab
may be down-titrated from a dose of 3 mg/kg
intravenously over time in order to discontinue
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the drug, although some patients may experience
disease flares during this tapering process.52
The dosing of corticosteroids also highlights a
down-titration approach. When corticosteroids
are used for anti-inflammatory or immunosuppressive effects, for instance, in the treatment of
asthma exacerbations, giant cell arteritis, rheumatoid arthritis, or systemic lupus erythematosus,
they usually require an initial short course with
dosing at the higher end of the dosing range to
achieve prompt control of symptoms. This is then
followed by gradual dose reductions over time to
the lowest dose that maintains the clinical
response or eventual discontinuation, thus minimizing the serious side effects that can occur with
long-term use of corticosteroids.36,53–56 A specific
example in allergic conditions is the use of a
methylprednisolone dose pack that starts with
24 mg orally on day 1, 20 mg on day 2, 16 mg on
day 3, 12 mg on day 4, 8 mg on day 5, and ends
with 4 mg on day 6.54,55 In these cases, down titration is utilized when rapid control of a disease
process is important and risks of acute toxicity
from high doses are minimal, but there is significant risk of harm associated with extended use of
higher doses or with use at any dose for long
durations.
Down-titration is also a method to prevent withdrawal or discontinuation syndromes and/or
other adverse effects. One example of this is the
tapering of prednisone in patients receiving
>20 mg/day orally (or the equivalent doses of
other corticosteroids) for >3 weeks to prevent
hypothalamic-pituitary-adrenal axis suppression.56,57 Another instance is the down-titration of
antidepressants by decreasing the dose over several weeks to prevent the discontinuation syndrome that may occur when stopping the
medication.49 Lastly, tapering the doses of benzodiazepines gradually over approximately 4–8 weeks
or more also illustrates the down-titration
approach to decrease the risk of benzodiazepine
withdrawal syndrome, which may include the
development of seizures. Down-titration may also
be based on a specific PK/PD parameter. As renal
function declines over time, such as in the setting
of acute kidney injury, certain drugs will be
titrated based on the Clcr. For instance, when
famotidine is used for the treatment of gastroesophageal reflux disease, it is given as 20 mg orally
twice daily. In the setting of renal impairment,
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famotidine is given as 20 mg once daily when the
Clcr is 30–60 ml/min and adjusted down to 20 mg
every other day or 10 mg once daily when the Clcr
is <30 ml/min. This approach is used to reduce
the risk of adverse effects as the renal function
declines.58 Changes in plasma protein binding of
a drug may also necessitate a dose titration.
Phenytoin concentrations need to be adjusted in
patients with low albumin, which may then lead
to the need for a decreased dose of phenytoin in
order to lower the risk of supra-therapeutic concentrations and adverse effects.11
Down-titration poses a unique challenge as
patients may be reluctant to decrease doses or
discontinue drugs that have provided symptom
control. Further, patients may not want to experience withdrawal or discontinuation syndromes.
With down-titration, the provider must be skillful in assuring the patient that the rate of downtitration can be adjusted as needed and
additional interventions can be used to help
manage symptoms related to decreasing the
dose.59,60 Like up-titration, providers may craft
their own down-titration regimens when there is
a lack of defined schedules, as with antidepressants, benzodiazepines, biologics, and corticosteroids.36,52,56,59,60 The down-titration schedule is
designed based on symptom severity, the urgency
with which symptom relief is needed, the degree
of clinical response, prior experience in clinical
practice and/or in an individual patient, and the
risks associated with recurrence of symptoms.52,54
Cross-titration
Cross-titration (or cross-tapering) in either direction may be performed when switching patients
from one medication to another or to enable
patients to be maintained on two medications, at
times allowing both to be used at lower doses
than when given alone.3,59 In the setting of crosstitration, both evidence-based resources and clinical expertise that apply to up- and down-titration
need to be considered for each individual drug
and patient, plus scrutiny regarding the safety of
using two specific drugs concomitantly, with particular consideration given to adverse effects and
drug interactions. A case in point is the titration
of lamotrigine when a patient is concurrently taking valproate. In this setting, lamotrigine is
titrated up, starting at a lower dose (25 mg every
other day rather than 25 mg daily) than when
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prescribed alone. This titration schedule is
adjusted to account for the interaction between
the two agents that decreases the clearance of
lamotrigine.48 Adding vasopressin, up to
0.03 units/min, to decrease the norepinephrine
dosage in sepsis and septic shock is an example of
using a lower dose of one agent when it is used in
combination with another drug. Using the drugs
in combination allows a lower dose of norepinephrine to be used while still maintaining mean
arterial pressure. The benefit of this approach
remains uncertain as no difference in mortality
was found in the clinical trial that evaluated this
practice. However, a subgroup analysis suggested
improved survival in patients who received vasopressin with norepinephrine doses <15 µg/min.44
Lastly, cross-titration when switching antidepressants highlights a down-titration of the current
agent until it can be discontinued while concurrently starting a new agent and up-titrating its
dose over time.59 This customized approach
allows continued control of depression symptoms
and avoidance of the antidepressant discontinuation syndrome.59
Complexities of drug titration
Evidence
Drug titration is a form of personalized medicine.2 There is mounting evidence that substantial treatment heterogeneity exists in both clinical
trials and real-world practice. This contradicts
the notion that all patients being treated with a
specific medication actually take the same dose,
for the same duration, and in combination with
the same concomitant medication(s).61–63 While
it is becoming clearer that a “one-size-fits-all”
approach is not optimal for drug dosing,17 clinical
trials with titrated medications are complex, as
comparisons between fixed-dose and dose-titration or between various dose-titration schedules,
are difficult to study. Such challenges include the
maintenance of blinding, external validity, and
increased potential for post-randomization biases
(i.e., differential loss to follow up, differential
adherence, and differential discontinuation).
In addition, it is difficult to establish real-world
evidence for titrated medications. When patients
do not have the same drug exposures (drug, dose,
duration, and concomitant medications), it is difficult to attribute specific clinical outcomes to

journals.sagepub.com/home/taw

AR Caffrey and EP Borrelli et al.
specific exposures. This challenge has been
described in infectious diseases, in which it was
found that treatment heterogeneity is nearly universal in bloodstream infections.62 Unfortunately,
there is a lack of real-world exposure data for
titrated medications, as data sources lack titration
details. As a result, it is difficult to substantiate
titration schedules, in terms of safety or effectiveness, since supportive data are unavailable.
Therefore, drug titration complicates our understanding of the effect of medications in real-world
practice.
Due to the lack of real-world evidence for titrated
medications, clinicians often must rely on data
from clinical trials to inform their prescribing of
schedules for drug titration, despite the aforementioned clinical trial limitations. However, it is
unclear whether titration schedules closely reflect
titration from clinical trials and/or labeled titration, and some evidence suggests not only wide
variation in titration schedules in clinical practice,
but also divergence in titration schedules from
clinical trials.43 For instance, a meta-analysis
determined that, out of 11 randomized clinical
trials and 38 cohort studies of methylphenidate
for the treatment of ADHD in children, only 2
and 8, respectively, reported their justification for
the dose range used in the study.64 However, the
justification was either unclear or did not match
the cited source in most of these studies, highlighting the lack of evidence supporting titration
schedules of methylphenidate in ADHD. In addition, there was a wide variation in the dose titration as the dose in the randomized clinical trials
ranged from 20 to 72 mg/day, whereas in the
cohort studies, it ranged from 20 to 60 mg/day.64
Also, in patients on medications for heart failure,
it was found that the up-titration schedules carried out in clinical trials by dedicated research
staff are not mirrored in the real-world setting,
where lower doses are generally prescribed in
contrast to the higher doses achieved in clinical
trials.65
Consensus
There may be a lack of consensus on titration
schedules that maximize benefits and minimize
harms,3,49 or a lack of consensus on the therapeutic and toxic concentration of the medication.3,11
One example of a drug that has indication-based
titration schedules is quetiapine. The initial dose

journals.sagepub.com/home/taw

and dose increases for the titration are dependent
on whether the drug is being used for schizophrenia, bipolar mania, or bipolar depression.14
Antiepileptic drugs demonstrate variability in
therapeutic versus toxic drug concentration ranges.
Some patients may experience seizure freedom at
concentrations that are below the defined reference range, while others may have a reduction in
seizures only when the concentrations are above
the range, thus suggesting that each patient has his
or her own individual target concentration.11 This
highlights that, although there may be a recommended titration schedule stemming from a “onesize-fits-all” approach based on prescribing
information or clinical guidelines, providers may
need to craft a titration regimen to best fit the
needs of an individual patient.
The benefits of up-titration to attain a specific
response with certain medications has been
uncertain. In 2002, the recommendation for
patients undergoing elective noncardiac surgery
per the American College of Cardiology/American
Heart Association Guideline for Perioperative
Cardiovascular Evaluation for Noncardiac
Surgery was to prescribe a beta-blocker days or
weeks before surgery and titrate the dose to
achieve a heart rate of 50–60 beats/min.66
However, in the 2014 guideline update, the recommendation was modified as the benefit of
starting beta-blockers in naïve patients prior to
surgery was called into question along with how
to titrate them in this setting.67 Such uncertainly
also exists with tapering (down-titrating) antidepressants. While some clinicians suggest decreasing the dose by 25% per week until the
antidepressant is discontinued, others recommend decreasing the dose by 25% per month.59
The protocol for benzodiazepine down-titration
is also not well defined, as the recommendations
range from decreasing the dose by 50% each week
to decreasing it by 10–25% every 2 weeks.60
Lastly, there may be an inability to measure
objective outcomes without a specific marker for
efficacy, effectiveness, or toxicity.2
Adherence
Further complicating the effectiveness and safety
of drug titration is the inconvenience to the
patient, which can impact medication adherence,
including under-dosing (delay or failure to
increase dose), over-dosing (initial high dose or
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rapid dose increases), and/or missed dosing. Drug
titration is also inconvenient in terms of healthcare-related visits for dose titrations and/or monitoring.1 Up to half of patients are non-adherent to
their chronic medications, without taking into
account the additional challenges surrounding
dose titration,3,68 and non-adherence is associated
with harmful health consequences and increased
healthcare costs.17,35 As described earlier, patients
may not take their medications or may not take
them as prescribed, for numerous reasons, which
includes complex regimens and adverse effects.3,35
Starter kits and dose packs, such as those mentioned previously for lamotrigine and methylprednisolone, help to facilitate adherence to specific
drug titration schedules.3,35,48,54,55 Titration packs
are convenient for the provider and the patient,
making it easier to adhere to a titrated regimen.
However, they may not meet the needs of all
patients, and, in some cases, may inadvertently
cater to a “one-size-fits-all” approach and interfere with personalized dosing.54,55
Although drug regimen complexity is recognized
as a risk factor for non-adherence with certain
medications, up-titration or down-titration also
alleviates adverse effects, as has been described
with antidepressants and anticonvulsants, potentially leading to improved adherence by reducing
treatment
interruptions
or
discontinuations.12,38,49,69–71 The need to coordinate care
among providers and between providers and
patients becomes more critical with drugs that
require titration, both to monitor for effectiveness
(or lack thereof) and adverse effects and to facilitate dose titration.3,65 However, clinicians have
limited time, inadequate support structures, and
unclear roles regarding drug titration.65
The complexities of drug titration affecting medication adherence are further complicated by
multi-morbidity. Overall, medication utilization
rates have increased over time, due to increases in
available medications on the market to treat diseases (e.g., medications for certain conditions
were not previously available), as well as increased
rates of chronic diseases due to the changing
health and life expectancy of the population
(increase in chronic diseases such as diabetes,
high blood pressure, high cholesterol, and greater
multi-morbidity in aging populations). Data from
the 2010 National Health and Nutrition
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Examination Survey (NHANES) found that
approximately 39% of people who are at least
65 years of age were taking at least five prescription medications.72 Patients taking complex medication regimens have been shown to have worse
medication adherence and patient outcomes. The
addition of medications requiring titration adds
further complexity to medication regimens for
patients, making it more difficult to understand
the dose and schedule, and, in turn, can reduce
patient adherence.1,3,35
Various strategies have been deployed to improve
and support drug titration in clinical practice. A
multidisciplinary healthcare approach can help
improve the quality of medication titration. In the
setting of heart failure, clinician education, decision support and communication tools, post-prescribing telephone monitoring of patients,
auditing of clinicians, transitions of care and disease management services, and expanded prescribing privileges for nurses and pharmacists
have been used to enable a more individualized
approach to pharmacotherapy.65 In addition,
nurse-led titration services of heart failure medications have achieved target doses sooner while
decreasing heart failure-related hospital admissions and increasing patient survival.73
Multidisciplinary teams that combine elements of
the above-described approaches that take into
account the best fit for the specific clinical practice site are more likely to be successful.65 Several
studies have shown that pharmacist run titration
services for insulin in patients with diabetes mellitus have resulted in improved glycemic control.74,75 Similar programs utilizing pharmacists
have been effective in the management of anticoagulation, neurologic conditions, and gout.76–78
Appropriate drug titration that results in better
patient outcomes may give rise to downstream
cost savings. A study with PGT-guided therapy in
bipolar disorder found a decrease in hospitalizations, a shorter duration of hospitalization, and
less use of emergency medical services, ultimately
leading to potential overall cost savings to the
healthcare system, as compared with non-PGT
guided therapy.79
Involving patients in the treatment decision-making process can improve adherence, particularly
when patient and provider expectations and
responsibilities to each other are clearly established.3 With a collaborative approach, patients
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can take an active role in guiding their drug titrations. For example, a majority of adults with
ADHD can identify when the effects of their
medications are wearing off.80 Providers can use
this information to fine tune the drug titrations
to improve symptom control over the course of
the day.80 Moreover, advances in information
technology should allow both clinicians and
patients to be partners in this individualized
approach to drug dosing.1 Information technology, for instance, electronic medical record systems, should assist in the collection and analysis
of data from the real-world setting, which can
then be used to inform clinical decision making
for personalized medicine.17
Costs
Medication titration is associated with excess
healthcare resource utilization and healthcare
costs. One study from a nationwide panel of neurologists showed that, for patients utilizing antiepileptic drugs, periods of titration incurred higher
healthcare resource utilization and costs compared with maintenance periods.81 Similarly, an
analysis of a large claims database found that for
patients with major depressive disorder who initiated therapy with a serotonin reuptake inhibitor,
those who underwent dose titration experienced
significantly higher healthcare resource utilization and healthcare costs after 8 weeks of therapy
compared with those who did not undergo
titration.82
While PGT has the potential to reduce titrationassociated cost, some important factors to consider for PGT are: who and when to test, which
test to select, and how to interpret and use the
test’s results.27,83 For certain conditions, providers may consider PGT to provide minimal clinical
information, and, therefore, not worth the
costs.27,83 Another barrier facing more widespread
utilization of PGT in the United States is that
third party payer reimbursement is highly variable
depending upon the plan, the type of testing, and
the specific test.83–86 Due to this, if PGT is not
covered by insurance, it is not likely patients will
pay out-of-pocket for the service, with a survey
showing that almost half of patients would not
pay any out-of-pocket costs for PGT.87
Titration can also lead to medication waste, as
dose changes may require different prescriptions
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for different strengths and thus lead to leftover
drug supply.88,89 Further, insurance plan policies
present a barrier to titration due to drug supply
requirements. For example, the 30- or 90-day
supply requirement for coverage of the prescription, despite titration occurring in shorter intervals, leads to an excess of medication being
dispensed to the patient.89,90 A complication of
this excess supply, as observed with opioids and
ADHD medications, is the potential for drug misuse or diversion.91–94 Titration can also lead to
prescription refill issues. There is the potential for
delay in therapy when the up-titration quantity
exceeds therapeutic quantity limits for lower
doses. In addition, up-titration with an existing
prescription, as instructed by a provider directly
to a patient, presents challenges at the time of
refill since, without knowledge of the up-titration,
insurance will consider it an early fill and deny
coverage.95–98
Excess costs due to healthcare utilization and prescriptions fills, and corresponding drug waste,
represent opportunities for improvement in drug
titration. Insurance companies should devise procedures and policies that support optimization of
drug titration. Further, increased acceptance of
telehealth could support healthcare visits specifically for titration, thus reducing associated healthcare costs of titration-related visits from both a
health system perspective, as well as direct and
indirect patient costs.
Summary
Drug titration is a form of personalized medicine,
and many drugs in a variety of therapeutic areas
require dose titration due to PK/PD and PGT
parameters, to achieve specific therapeutic goals,
and/or to decrease the risk of adverse effects. For
some drugs, all of these factors may be interrelated, leading to the necessity of an individualized, patient-centered approach that blends
together the art and science of drug titration. This
is in contrast to the population-based approach of
“one-size-fits-all” dosing, which may not be as
equally safe and effective among all patients.
There is a paucity of real-world data on the effectiveness and safety of specific titration schedules
among titrated medications, hence the varied
approaches to titration and lack of titration consensus for many medications. The widespread
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use of electronic medical records and integration
of medical and pharmacy records provides a
unique opportunity to consistently and accurately
capture titration details in a standardized manner. In turn, such documentation will improve
the coordination of care between providers and
patients, and enable research that produces realworld evidence to minimize harms and maximize
positive clinical outcomes among titrated
medications.
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